Sign in Subscribe
Pharmaceutical industry

Generex Biotechnology Presents Clinical Data at Diabetes Technology Meeting

Strategic Insights

— 1 min read

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases, announced its participation in the 6th Annual Diabetes Technology Meeting in Atlanta, Georgia. The company presented two poster presentations of clinical data on its proprietary oral insulin spray product, Generex Oral-lyn, and metformin gum, a collaborative project with Fertin Pharma A/S. The goal of the meeting was to facilitate the creation of new tools to help people with diabetes, with a focus on original data.

Key Takeaways:

  • Generex Biotechnology presented two poster presentations of clinical data at the 6th Annual Diabetes Technology Meeting in Atlanta, Georgia.
  • The data relates to Generex Oral-lyn, a proprietary oral insulin spray product designed to replace prandial insulin injections, and Generex Metformin Gum, a proprietary alternative delivery format for metformin.
  • The goal of the meeting was to facilitate the creation of new tools to help people with diabetes, with a focus on original data.
  • The first poster presentation, "3-Month Interim Results (6-Month Study) on Safety and Efficacy of an Oral Insulin (Generex Oral-lyn(TM)) Administered at Lunchtime in Juvenile Type-1 Diabetes Mellitus Subjects Maintained on Basal Glargine Insulin and Pre-Breakfast and Pre-Dinner Regular Insulin," was co-authored by Drs. Jaime Guevara-Aguirre, Marco Guevara-Aguirre, and Jeannette Saavedra.
  • The second poster presentation, "Metformin Gum: An Alternative Method for Delivery of Biguanides," was authored by Drs. Jaime Guevara-Aguirre, David Saldarreaga, Marco Guevara-Aguirre, and Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito, Ecuador, and Dr. Gerald Bernstein, Generex's Vice-President - Medical Affairs.
  • Generex Oral-lyn is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, and is in various stages of clinical trials around the world.

Statistics:

  • The 6th Annual Diabetes Technology Meeting took place from November 2-4, 2006, in Atlanta, Georgia.
  • Generex presented two poster presentations of clinical data at the meeting.
  • The Institute of Endocrinology IEMYR in Quito, Ecuador, is involved in the development of Generex Oral-lyn.
  • Dr. Gerald Bernstein, Generex's Vice-President - Medical Affairs, co-authored the second poster presentation.
  • Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).

Sources:

  • Generex Biotechnology Corporation (NASDAQ: GNBT)
  • Diabetes Technology Society (www.diabetestechnology.org)
  • Institute of Endocrinology IEMYR in Quito, Ecuador
  • Fertin Pharma A/S
  • Market Wire via COMTEX (Oct 31, 2006)

Read more